Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence-Reference-Cited by-同舟云学术

Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence

Published:2017-01 Issue:1 Volume:282 Page:212-221
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Kim Cherry,Kim Ho Sung,Shim Woo Hyun,Choi Choong Gon,Kim Sang Joon,Kim Jeong Hoon

Funder

National Research Foundation of Korea

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2016152152

Reference27 articles.

1. Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

2. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

3. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

4. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

5. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas;Chinese Neurosurgical Journal;2024-07-24

2. A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas;Journal of Clinical Medicine;2022-06-30

3. Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation;Journal of Cancer;2022

4. Cerebral and tumoral blood flow in adult gliomas: a systematic review of results from magnetic resonance imaging;The British Journal of Radiology;2021-09-01

5. Forkhead box O1 targeting replication factor C subunit 2 expression promotes glioma temozolomide resistance and survival;Annals of Translational Medicine;2021-04